148 related articles for article (PubMed ID: 35078225)
1. Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study.
Sherbini AA; Gwinnutt JM; Hyrich KL; ; Verstappen SMM
Rheumatology (Oxford); 2022 Oct; 61(10):3930-3938. PubMed ID: 35078225
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review.
Sherbini AA; Sharma SD; Gwinnutt JM; Hyrich KL; Verstappen SMM
Rheumatology (Oxford); 2021 Sep; 60(9):4001-4017. PubMed ID: 33909898
[TBL] [Abstract][Full Text] [Related]
3. Relationship between frailty and methotrexate discontinuation due to adverse events in rheumatoid arthritis patients.
Sobue Y; Suzuki M; Ohashi Y; Koshima H; Okui N; Funahashi K; Ishikawa H; Inoue H; Asai S; Terabe K; Kishimoto K; Kihira D; Maeda M; Sato R; Imagama S
Clin Rheumatol; 2023 Aug; 42(8):2069-2077. PubMed ID: 37211570
[TBL] [Abstract][Full Text] [Related]
4. The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate.
Hope HF; Hyrich KL; Anderson J; Bluett J; Sergeant JC; Barton A; Cordingley L; Verstappen SMM;
Rheumatology (Oxford); 2020 Jan; 59(1):213-223. PubMed ID: 31302692
[TBL] [Abstract][Full Text] [Related]
5. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study.
Verstappen SM; Bakker MF; Heurkens AH; van der Veen MJ; Kruize AA; Geurts MA; Bijlsma JW; Jacobs JW;
Ann Rheum Dis; 2010 Jun; 69(6):1044-8. PubMed ID: 19581281
[TBL] [Abstract][Full Text] [Related]
6. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
[TBL] [Abstract][Full Text] [Related]
7. Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS).
Sergeant JC; Hyrich KL; Anderson J; Kopec-Harding K; Hope HF; Symmons DPM; ; Barton A; Verstappen SMM
Arthritis Res Ther; 2018 Jul; 20(1):147. PubMed ID: 30005689
[TBL] [Abstract][Full Text] [Related]
8. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
9. [Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice].
La Montagna G; Tirri R; Vitello R; Malesci D; Buono R; Mennillo G; Valentini G
Reumatismo; 2006; 58(4):261-7. PubMed ID: 17216014
[TBL] [Abstract][Full Text] [Related]
10. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
Shea B; Swinden MV; Tanjong Ghogomu E; Ortiz Z; Katchamart W; Rader T; Bombardier C; Wells GA; Tugwell P
Cochrane Database Syst Rev; 2013 May; 2013(5):CD000951. PubMed ID: 23728635
[TBL] [Abstract][Full Text] [Related]
11. Search of official nationwide database in Japan for adverse events associated with disease-modifying antirheumatic drug therapies: focus on therapies in combination with methotrexate.
Inokuma S
Expert Opin Drug Saf; 2022 Apr; 21(4):573-580. PubMed ID: 34762577
[TBL] [Abstract][Full Text] [Related]
12. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.
Curtis JR; Beukelman T; Onofrei A; Cassell S; Greenberg JD; Kavanaugh A; Reed G; Strand V; Kremer JM
Ann Rheum Dis; 2010 Jan; 69(1):43-7. PubMed ID: 19147616
[TBL] [Abstract][Full Text] [Related]
13. [Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis].
Nesa L; Gobbi C; Alba P; Exeni I; Babini A; Albiero E
Rev Fac Cien Med Univ Nac Cordoba; 2007; 64(4):109-14. PubMed ID: 19928400
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of low-dose tacrolimus for active rheumatoid arthritis with an inadequate response to methotrexate.
Lee WS; Lee SI; Lee MS; Kim SI; Lee SS; Yoo WH
Korean J Intern Med; 2016 Jul; 31(4):779-87. PubMed ID: 26961485
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
[TBL] [Abstract][Full Text] [Related]
16. Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study.
Nash P; Nicholls D
Int J Rheum Dis; 2013 Dec; 16(6):652-61. PubMed ID: 24382276
[TBL] [Abstract][Full Text] [Related]
17. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.
Schiff M; Weinblatt ME; Valente R; van der Heijde D; Citera G; Elegbe A; Maldonado M; Fleischmann R
Ann Rheum Dis; 2014 Jan; 73(1):86-94. PubMed ID: 23962455
[TBL] [Abstract][Full Text] [Related]
18. Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.
Quach LT; Chang BH; Brophy MT; Soe Thwin S; Hannagan K; O'Dell JR
Rheumatology (Oxford); 2017 Mar; 56(3):378-383. PubMed ID: 27994091
[TBL] [Abstract][Full Text] [Related]
19. Adverse Effects of Low-Dose Methotrexate: A Randomized Trial.
Solomon DH; Glynn RJ; Karlson EW; Lu F; Corrigan C; Colls J; Xu C; MacFadyen J; Barbhaiya M; Berliner N; Dellaripa PF; Everett BM; Pradhan AD; Hammond SP; Murray M; Rao DA; Ritter SY; Rutherford A; Sparks JA; Stratton J; Suh DH; Tedeschi SK; Vanni KMM; Paynter NP; Ridker PM
Ann Intern Med; 2020 Mar; 172(6):369-380. PubMed ID: 32066146
[TBL] [Abstract][Full Text] [Related]
20. Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort.
Nikiphorou E; Negoescu A; Fitzpatrick JD; Goudie CT; Badcock A; Östör AJ; Malaviya AP
Clin Rheumatol; 2014 May; 33(5):609-14. PubMed ID: 24609758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
